$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

$bmrn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000104847724000070 Filed on April 26, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$712.0M	$648.8M
YoY Change	19.61%	8.79%
Cost Of Revenue	$130.5M	$125.2M
YoY Change	1.86%	-1.08%
Gross Profit	$581.6M	$523.7M
YoY Change	24.48%	11.45%
Gross Profit Margin	81.68%	80.71%
Selling, General & Admin	$263.0M	$225.9M
YoY Change	22.15%	1.3%
% of Gross Profit	45.23%	43.14%
Research & Development	$183.8M	$205.0M
YoY Change	3.62%	19.29%
% of Gross Profit	31.6%	39.15%
Depreciation & Amortization	$11.50M	$27.35M
YoY Change	-54.76%	3.52%
% of Gross Profit	1.98%	5.22%
Operating Expenses	$446.8M	$445.2M
YoY Change	9.43%	12.75%
Operating Profit	$120.5M	$78.46M
YoY Change	104.61%	32.21%
Interest Expense	$16.21M	$15.82M
YoY Change	83.03%	327.17%
% of Operating Profit	13.46%	20.16%
Other Income/Expense, Net	-$4.527M	$1.267M
YoY Change	-246.84%	-111.7%
Pretax Income	$132.1M	$105.5M
YoY Change	86.61%	85.96%
Income Tax	$24.96M	$16.89M
% Of Pretax Income	18.89%	16.0%
Net Earnings	$107.2M	$88.66M
YoY Change	91.25%	74.35%
Net Earnings / Revenue	15.05%	13.66%
Basic Earnings Per Share	$0.56	$0.47
Diluted Earnings Per Share	$0.55	$0.45
COMMON SHARES
Basic Shares Outstanding	189.9M shares	188.7M shares
Diluted Shares Outstanding	200.5M shares	199.3M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.224B	$1.047B
YoY Change	4.56%	-9.16%
Cash & Equivalents	$972.2M	$747.0M
Short-Term Investments	$252.2M	$299.6M
Other Short-Term Assets	$160.4M	$163.3M
YoY Change	-17.05%	-5.71%
Inventory	$1.184B	$1.138B
Prepaid Expenses
Receivables	$691.2M	$637.2M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$3.260B	$2.985B
YoY Change	10.49%	5.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.053B	$1.060B
YoY Change	-1.35%	-0.72%
Goodwill	$196.2M	$196.2M
YoY Change	0.0%	0.0%
Intangibles	$265.5M	$279.7M
YoY Change	-14.44%	-14.21%
Long-Term Investments	$563.8M	$631.9M
YoY Change	46.14%	85.49%
Other Assets	$190.8M	$1.720B
YoY Change	-88.46%	1045.92%
Total Long-Term Assets	$3.807B	$3.888B
YoY Change	5.38%	8.24%
TOTAL ASSETS
Total Short-Term Assets	$3.260B	$2.985B
Total Long-Term Assets	$3.807B	$3.888B
Total Assets	$7.067B	$6.873B
YoY Change	7.68%	6.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$257.4M	$292.2M
YoY Change	-7.39%	-51.15%
Accrued Expenses	$298.4M	$274.9M
YoY Change	2.53%	-10.62%
Deferred Revenue	$1.912M	$5.151M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$494.8M	$494.4M
YoY Change
Total Short-Term Liabilities	$1.067B	$1.088B
YoY Change	78.71%	81.85%
LONG-TERM LIABILITIES
Long-Term Debt	$594.1M	$593.6M
YoY Change	-45.24%	-45.24%
Other Long-Term Liabilities	$119.4M	$117.4M
YoY Change	21.66%	26.98%
Total Long-Term Liabilities	$119.4M	$711.0M
YoY Change	-89.91%	669.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.067B	$1.088B
Total Long-Term Liabilities	$119.4M	$711.0M
Total Liabilities	$1.781B	$1.799B
YoY Change	0.03%	1.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$425.7M	-$532.9M
YoY Change	-37.61%	-27.83%
Common Stock	$5.697B	$5.619B
YoY Change	3.69%	3.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.286B	$5.074B
YoY Change
Total Liabilities & Shareholders Equity	$7.067B	$6.873B
YoY Change	7.68%	6.82%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$107.2M	$88.66M
YoY Change	91.25%	74.35%
Depreciation, Depletion And Amortization	$11.50M	$27.35M
YoY Change	-54.76%	3.52%
Cash From Operating Activities	$118.8M	$46.97M
YoY Change	69.51%	-163.53%
INVESTING ACTIVITIES
Capital Expenditures	$21.84M	$34.10M
YoY Change	-3.92%	39.45%
Acquisitions
YoY Change
Other Investing Activities	$112.3M	$19.87M
YoY Change	114.92%	-478.73%
Cash From Investing Activities	$90.48M	-$14.24M
YoY Change	206.4%	-52.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.61M	-42.79M
YoY Change	5.43%	5.03%
NET CHANGE
Cash From Operating Activities	118.8M	46.97M
Cash From Investing Activities	90.48M	-14.24M
Cash From Financing Activities	12.61M	-42.79M
Net Change In Cash	221.9M	-10.06M
YoY Change	98.87%	-93.04%
FREE CASH FLOW
Cash From Operating Activities	$118.8M	$46.97M
Capital Expenditures	$21.84M	$34.10M
Free Cash Flow	$96.92M	$12.87M
YoY Change	104.77%	-113.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	50852000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	648833000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	596415000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	125180000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	135472000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	204987000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	171846000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	225906000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	211023000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14298000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15670000	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	10000000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	560371000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	534011000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	88462000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	62404000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	19365000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	11943000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	3547000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3703000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1267000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-13887000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	105547000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	56757000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16885000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5905000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	88662000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	50852000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.46
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188866000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	186667000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	199262000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	194363000	shares
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	116404000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	43997000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	746996000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	755127000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	299584000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	318683000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	637163000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	633704000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1137982000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1107183000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	163287000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	141391000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	2985012000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2956088000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	620551000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	611135000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1060425000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1066133000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	279653000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	294701000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	196199000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	196199000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1546043000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1545809000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	184790000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	171538000	usd
CY2024Q1	us-gaap	Assets Assets	6872673000	usd
CY2023Q4	us-gaap	Assets Assets	6841603000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	593543000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	683147000	usd
CY2024Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	494357000	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	493877000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1087900000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1177024000	usd
CY2024Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	593605000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	593095000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	117352000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	119935000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1798857000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1890054000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	189776577	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	189776577	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	188598154	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	188598154	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	190000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	189000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5619264000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5611562000	usd
CY2024Q1	us-gaap	Common Stock Issued Employee Stock Trust CommonStockIssuedEmployeeStockTrust	11700000	usd
CY2023Q4	us-gaap	Common Stock Issued Employee Stock Trust CommonStockIssuedEmployeeStockTrust	9860000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1046000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-28788000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-532892000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-621554000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	5073816000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4951549000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6872673000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6841603000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4951549000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4603156000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	5073816000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4659043000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	88662000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27350000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26421000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	990000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1029000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2502000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1970000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	58249000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	53695000	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	10000000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	12650000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	285000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6360000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	10804000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-6615000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-127000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	222000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3386000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	138796000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16820000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14098000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	17353000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	36001000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	12130000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	323000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-59006000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-31686000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3309000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	4262000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	46971000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73932000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26104000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24456000	usd
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	131533000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	215118000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	121665000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	220364000	usd
CY2024Q1	bmrn	Proceeds From Sale Of Nonfinancial Assets ProceedsFromSaleOfNonfinancialAssets	10000000	usd
CY2023Q1	bmrn	Proceeds From Sale Of Nonfinancial Assets ProceedsFromSaleOfNonfinancialAssets	0	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8000000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	310000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14236000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-30012000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7197000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	21169000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	49948000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	51422000	usd
CY2024Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	9475000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	42000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1014000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-42793000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-40742000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1927000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	229000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8131000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-144457000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	755127000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	724531000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	746996000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	580074000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1420000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1437000	usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	2301000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	4364000	usd
CY2024Q1	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets	8167000	usd
CY2023Q1	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets	-8430000	usd
CY2024Q1	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets	-8512000	usd
CY2023Q1	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets	-1478000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div>
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	867089000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1060425000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1066133000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	12600000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	10300000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1668256000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1787000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2912000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1667131000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	746996000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	299584000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	620551000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1683827000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4388000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3270000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1684945000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	755127000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	318683000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	611135000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	12600000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	148140000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	155704000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	599462000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	571107000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	390380000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	380372000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1137982000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1107183000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1948434000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1933222000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	888009000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	709730000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	710011000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	430077000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	415310000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	279653000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	294701000	usd
CY2024Q1	bmrn	Milestone Payments Received MilestonePaymentsReceived	10000000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	292238000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	315509000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	148479000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	201067000	usd
CY2024Q1	bmrn	Accrued Government And Other Rebates AccruedGovernmentAndOtherRebates	101599000	usd
CY2023Q4	bmrn	Accrued Government And Other Rebates AccruedGovernmentAndOtherRebates	96179000	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	13676000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	33853000	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	10188000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	14299000	usd
CY2024Q1	bmrn	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	8574000	usd
CY2023Q4	bmrn	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	8779000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	6071000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2651000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5151000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4620000	usd
CY2024Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	7567000	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	6190000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	593543000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	683147000	usd
CY2024Q1	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	15356000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	9065000	usd
CY2024Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	16188000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	42024000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1100000000	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	1087962000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1086972000	usd
CY2024Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1083677000	usd
CY2023Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1107548000	usd
CY2024Q1	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	26618000	usd
CY2024Q1	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	-615000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-509000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	27742000	usd
CY2023Q1	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	-2612000	usd
CY2023Q1	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	3014000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	1229000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6855000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	648833000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	596415000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	58249000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	53695000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	88662000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	50852000	usd
CY2024Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	2769000	usd
CY2023Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	937000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	91431000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	51789000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188866000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	186667000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	199262000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	194363000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.46
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10947000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12975000	shares
CY2024Q1	bmrn	Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones	738600000	usd
CY2024Q1	bmrn	Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones To Be Paid Remainder Of Fiscal Year ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestonesToBePaidRemainderOfFiscalYear	16400000	usd
CY2024Q1	us-gaap	Purchase Obligation PurchaseObligation	386700000	usd
CY2024Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	340600000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001048477-24-000070-index-headers.html	Edgar Link	pending
0001048477-24-000070-index.html	Edgar Link	pending
0001048477-24-000070.txt	Edgar Link	pending
0001048477-24-000070-xbrl.zip	Edgar Link	pending
bmrn-20240331.htm	Edgar Link	pending
bmrn-20240331.xsd	Edgar Link	pending
bmrn-exx101xq12024.htm	Edgar Link	pending
bmrn-exx181xq12024.htm	Edgar Link	pending
bmrn-exx311xq12024.htm	Edgar Link	pending
bmrn-exx312xq12024.htm	Edgar Link	pending
bmrn-exx321xq12024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image.jpg	Edgar Link	pending
image1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
bmrn-20240331_cal.xml	Edgar Link	unprocessable
bmrn-20240331_def.xml	Edgar Link	unprocessable
bmrn-20240331_lab.xml	Edgar Link	unprocessable
bmrn-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bmrn-20240331_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2024 Q2 Form 10-Q Financial Statement

#000104847724000070 Filed on April 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2024 Q2 Form 10-Q Financial Statement

#000104847724000070 Filed on April 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn